From Canada.com:
The Supreme Court of Canada blocked the sale of a generic version of a popular blood-thinning drug in a ruling Thursday that reinforced patent protection to encourage brand-name pharmaceutical companies and other businesses to invest time and money into research.
The court unanimously dismissed generic drug-maker Apotex's bid to quash a Canadian patent for best-seller Plavix, which expires in 2012.
The ruling settles an intellectual property dispute over the validity of secondary patents that give drug companies protection, not only for their original inventions, but for an entire family of possible chemical compounds that encourage scientists to go back to the laboratory to improve a product. ...more
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment